The recovery from taxane mediated apoptosis in PC-3 castration-resistant metastatic prostate cancer cells

被引:1
|
作者
Eskiler, Gamze Guney [1 ]
Ozkan, Asuman Deveci [1 ]
Elmas, Merve Acikel [2 ]
Ozturk, Melek [3 ]
Arbak, Serap [2 ]
机构
[1] Sakarya Univ, Fac Med, Dept Med Biol, Korucuk Campus, TR-54290 Sakarya, Turkiye
[2] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Histol & Embryol, Istanbul, Turkiye
[3] Istanbul Cerrahpasa Univ, Fac Med, Dept Med Biol, Istanbul, Turkiye
关键词
Castration resistant metastatic prostate cancer; cells; Drug resistance; Apoptosis; Taxanes; Cabazitaxel; DNA-DAMAGE; CABAZITAXEL;
D O I
10.1016/j.tiv.2024.105894
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Here, we revealed the reversibility of cabazitaxel (CBZ)-induced apoptosis in PC-3 castration resistant metastatic prostate cancer cells (mCRPC) through the hallmarks of apoptosis. The recovery of PC-3 cells from apoptosis upon removal of CBZ at different recovery periods was evaluated by Annexin V, DNA damage, oxidative damage, mitochondrial membrane depolarization, and caspase activation. Our results showed that the administration of CBZ caused apoptosis for 72 h in PC-3 cells. However, recovered cells exhibited decreased nuclear damage, plasma membrane disruption, ROS level, release cytochrome c level and caspase-3 activation with upregulation of Bcl-2 expression upon removal of especially 1 nM CBZ for 24 h recovery period in PC-3 cells. Our study indicates that CBZ treated PC-3 cells can recover after apoptotic cell death. However, advanced molecular analysis should elucidate the relationship between the molecular mechanisms of recovery and taxane response or resistance in PC-3 mCRPC cells.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [42] Targeting Bone Metastatic Castration-Resistant Prostate Cancer
    Cook, Leah M.
    Lynch, Conor C.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (08) : 17 - 22
  • [43] Olaparib for Metastatic Castration-Resistant Prostate Cancer REPLY
    de Bono, Johann
    Kang, Jinyu
    Hussain, Maha
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 891 - 891
  • [44] Comment on: Rucaparib in castration-resistant, metastatic prostate cancer
    Brandt, Maximilian
    AKTUELLE UROLOGIE, 2024, 55 (02) : 98 - 98
  • [45] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    DRUGS, 2011, 71 (15) : 2067 - 2077
  • [46] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Abiraterone AcetateIn Metastatic Castration-Resistant Prostate Cancer
    Lily P. H. Yang
    Drugs, 2011, 71 : 2067 - 2077
  • [48] Metastatic castration-resistant prostate cancer: time for innovation
    Tucci, Marcello
    Scagliotti, Giorgio Vittorio
    Vignani, Francesca
    FUTURE ONCOLOGY, 2015, 11 (01) : 91 - 106
  • [49] Development of enzalutamide for metastatic castration-resistant prostate cancer
    Bhattacharya, Suman
    Hirmand, Mohammad
    Phung, De
    van Os, Steve
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 13 - 27
  • [50] Advancing therapies in metastatic castration-resistant prostate cancer
    Baciarello, Giulia
    Gizzi, Marco
    Fizazi, Karim
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (16) : 1797 - 1804